Susan Reckling


Authored Items

Adjuvant Chemotherapy Reduces Local and Regional Tumor Recurrence, Especially for Patients with ER-Negative Breast Cancer

March 2013, Highlights - Chemotherapy

Adjuvant chemotherapy should be recommended for patients with completely resected, isolated local or regional recurrence (ILRR) of breast cancer, and the argument is strongest for women with estrogen receptor (ER)-positive tumor recurrences, according to the results of the international Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer (CALOR) trial.

[ Read More ]

HER2 Status Determined by Central Laboratory Testing May Be More Reliable than Routine Local Testing

March 2013, Highlights - Breast Cancer

Determining HER2 status utilizing novel central laboratory testing techniques has been shown to be more reliable than routine local HER2 testing, such as immunohistochemistry or in situ hybridization. This finding for patients with HER2-positive breast cancer may lead to future therapeutic applications for patients with HER2-negative breast cancer as well.

[ Read More ]

Results of Immunohistochemistry and In Situ Hybridization Reliable Indicators of HER2-Positive Status

March 2013, Highlights - Breast Cancer

The incidence of false-negative immunohistochemistry (IHC) is only 1% in patients with primary breast cancer, according to a prospective multicenter Canadian study presented at the meeting. This is good news in relation to standardized testing utilizing IHC and in situ hybridization techniques for the accurate diagnosis of patients expressing HER2.

[ Read More ]